FLAURA2 data show osimertinib plus chemotherapy significantly improves overall survival vs osimertinib alone in frontline EGFR+ advanced NSCLC.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, discusses how precision supportive care tailors interventions to patient needs.

Lutetium Li 177 dotatate was linked with partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors, per real-world data.

Benjamin Besse, MD, PhD, shares AE management strategies with amivantamab/lazertinib in EGFR-positive NSCLC following CHRYSALIS-2 results.

Read an advanced practice nurse's tips for treating patients with endometrial cancer with durvalumab.

Panelists discuss how they approach long-term monitoring and follow-up care for patients who have ALK-positive+ patients disease to maintain optimal outcomes on stable therapy.

Panelists discuss how practice improvements and patient resources can be implemented to empower both health care providers and patients who have ALK-positive disease.

Relacorilant’s new drug application for platinum-resistant ovarian cancer has been accepted by the FDA.

Tepotinib was associated with frequent but manageable adverse events in MET exon 14–positive NSCLC, with peripheral edema most common.

Formerly known as TAR-200, gemcitabine intravesical system has received the FDA’s approval for use in patients with BCG-unresponsive NMIBC.

Ghayas C. Issa, MD, MS, discusses key adverse events of menin inhibitors in NPM1-mutated and KMT2Ar AML.

Adding ivonescimab to chemotherapy improved PFS for patients with EGFR-mutated non–small cell lung cancer after treatment with a third-generation TKI.

Expert Kelsey Martin shares nursing insights on balancing glucose control and GI side effects when caring for patients on PI3K and AKT inhibitors.

New AQUILA data show PFS improvement in patients with smoldering multiple myeloma who were treated with subcutaneous daratumumab vs active monitoring.

Mortality, progression, and venous thromboembolism were among outcomes improved for patients with polycythemia vera taking a GLP-1a.

Familiarity with each component of antibody-drug conjugates helps nurses and APPs deliver proactive adverse event management to patients with cancer.

Patients with intermediate- or high-risk MDS experienced a higher modified overall response rate with the venetoclax/azacitidine vs placebo/azacitidine.

Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology.

Biology-guided radiotherapy involves teamwork across multiple specialists, according to Samantha Bianzon, BSN, RN.

Panelists discuss how patient education strategies support long-term treatment success, adherence, and shared decision-making.

Panelists discuss how they monitor and educate patients on ALK inhibitor side adverse effects while equipping nursing staff to manage toxicities proactively.

Understanding which patients may benefit from CLDN6-targeting immunotherapy and recognizing potential adverse effects is essential for oncology nurses.

Karolina Faysman, NP, explains how step-up dosing is used to reduce CRS and ICANS with bispecific antibodies in multiple myeloma.

Nurses must stay up to date on novel agents and their toxicities to properly monitor for and manage immune effector cell-associated neurotoxicity syndrome.